212 related articles for article (PubMed ID: 31715340)
1. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider.
Tripto-Shkolnik L; Fund N; Rouach V; Chodick G; Shalev V; Goldshtein I
Bone; 2020 Jan; 130():115150. PubMed ID: 31715340
[TBL] [Abstract][Full Text] [Related]
2. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
3. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
[TBL] [Abstract][Full Text] [Related]
4. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Burckhardt P; Faouzi M; Buclin T; Lamy O;
J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
[TBL] [Abstract][Full Text] [Related]
5. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
[TBL] [Abstract][Full Text] [Related]
6. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
7. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
8. Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea.
Cha S; Sohn M; Yang H; Yeh EJ; Baek KH; Ha J; Ku H
BMC Musculoskelet Disord; 2024 Jan; 25(1):76. PubMed ID: 38245776
[TBL] [Abstract][Full Text] [Related]
9. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
11. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series.
Tripto-Shkolnik L; Liel Y; Yekutiel N; Goldshtein I
Horm Metab Res; 2021 Mar; 53(3):185-190. PubMed ID: 33588445
[TBL] [Abstract][Full Text] [Related]
13. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.
Zeytinoglu M; Naaman SC; Dickens LT
Endocrinol Metab Clin North Am; 2021 Jun; 50(2):205-222. PubMed ID: 34023039
[TBL] [Abstract][Full Text] [Related]
14. Denosumab Discontinuation.
Sølling AS; Tsourdi E; Harsløf T; Langdahl BL
Curr Osteoporos Rep; 2023 Feb; 21(1):95-103. PubMed ID: 36564572
[TBL] [Abstract][Full Text] [Related]
15. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
16. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
17. Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report.
Koiwai H; Kamimura M; Nakamura Y; Takahashi J; Taguchi A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):178-181. PubMed ID: 33019908
[TBL] [Abstract][Full Text] [Related]
18. How the COVID-19 pandemic affected bone health: a retrospective, longitudinal study on denosumab persistence from the epicentre of European spreading.
Varenna M; Orsini F; Di Taranto R; Zucchi F; Manara M; Caporali R; Crotti C
Arch Osteoporos; 2023 Jul; 18(1):95. PubMed ID: 37438617
[TBL] [Abstract][Full Text] [Related]
19. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
[TBL] [Abstract][Full Text] [Related]
20. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.
Imel EA; Starzyk K; Gliklich R; Weiss RJ; Wang Y; Williams SA
Osteoporos Int; 2020 Dec; 31(12):2413-2424. PubMed ID: 32696118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
